Screening for left ventricular hypertrophy in patients with type 2 diabetes mellitus in the community

Cardiovascular Diabetology

Volumn 10, Issue , 2011, Pages

  Somaratne, Jithendra B ^a   Whalley, Gillian A ^a   Poppe, Katrina K ^a   ter Bals, Mariska M ^a   Wadams, Gina ^a   Pearl, Ann ^a   Bagg, Warwick ^a   Doughty, Rob N ^a  

^a THE UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMMUNITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETIC PATIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE DURATION; DISEASE SEVERITY; DYSLIPIDEMIA; ELECTRIC POTENTIAL; ELECTROCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SCREENING TEST; SENSITIVITY AND SPECIFICITY; BLOOD; METHODOLOGY; PATHOPHYSIOLOGY;

CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES;

EID: 79953874328     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-10-29     Document Type: Article

References (30)

1. American Diabetes Association Standards of Medical Care in Diabetes - 2007. Diabetes Care 2007, 30(suppl_1):S4-41. American Diabetes Association.
2. Adult Treatment Panel III Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002, 106(25):3143. Adult Treatment Panel III.
3. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocrine Reviews 2004, 25(4):543-567. 10.1210/er.2003-0012, 15294881.
4. Magnusson M, Jovinge S, Shahgaldi K, Israelsson B, Groop L, Melander O. Brain natriuretic peptide is related to diastolic dysfunction whereas urinary albumin excretion rate is related to left ventricular mass in asymptomatic type 2 diabetes patients. Cardiovascular Diabetology 2010, 9(1):2. 10.1186/1475-2840-9-2, 2817679, 20078898.
5. Romano S, Di Mauro M, Fratini S, Guarracini L, Guarracini F, Poccia G, Penco M. Early diagnosis of left ventricular diastolic dysfunction in diabetic patients: a possible role for natriuretic peptides. Cardiovascular Diabetology 2010, 9(1):89. 10.1186/1475-2840-9-89, 3019186, 21162718.
6. Palmieri V, Tracy RP, Roman MJ, Liu JE, Best LG, Bella JN, Robbins DC, Howard BV, Devereux RB, Strong Heart S. Relation of left ventricular hypertrophy to inflammation and albuminuria in adults with type 2 diabetes: the Strong Heart Study. Diabetes Care 2003, 26(10):2764-2769. 10.2337/diacare.26.10.2764, 14514577.
7. Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocardiographic Left Ventricular Hypertrophy and Risk of Coronary Heart Disease. Annals of Internal Medicine 1970, 72(6):813-822.
8. Verdecchia P, Angeli F, Borgioni C, Gattobigio R, de Simone G, Devereux RB, Porcellati C. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. American Journal of Hypertension 2003, 16(11 Pt 1):895-899. 10.1016/S0895-7061(03)01018-5, 14573325.
9. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlöf B. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004, 292(19):2350-2356. 10.1001/jama.292.19.2350, 15547162.
10. Dawson A, Rana BS, Pringle SD, Donnelly LA, Morris AD, Struthers AD. How much echo left ventricular hypertrophy would be missed in diabetics by applying the Losartan Intervention For Endpoint Reduction electrocardiogram criteria to select patients for angiotensin receptor blockade?. Journal of Hypertension 2004, 22(7):1403-1408. 10.1097/01.hjh.0000125408.50839.b8, 15201558.
11. Maeder MT, Mariani JA, Kaye DM. Hemodynamic Determinants of Myocardial B-Type Natriuretic Peptide Release: Relative Contributions of Systolic and Diastolic Wall Stress. Hypertension 2010, 56(4):682-689. 10.1161/HYPERTENSIONAHA.110.156547, 20713912.
12. Fang ZY, Schull-Meade R, Leano R, Mottram PM, Prins JB, Marwick TH. Screening for heart disease in diabetic subjects. American Heart Journal 2005, 149(2):349-354. 10.1016/j.ahj.2004.06.021, 15846276.
13. Limkakeng AT, Drake W, Mani G, Freeman D, Best R, Newby LK, Chandra A. Left ventricular dysfunction screening in hypertensive patients with N-terminal pro-B-type natriuretic peptide and electrocardiogram. The American Journal of Emergency Medicine 2010, Corrected Proof.
14. Wright SP, Doughty RN, Pearl A, Gamble GD, Whalley GA, Walsh HJ, Gordon G, Bagg W, Oxenham H, Yandle T, et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. Journal of the American College of Cardiology 2003, 42(10):1793-1800. 10.1016/j.jacc.2003.05.011, 14642690.
15. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. Journal of the American Society of Echocardiography 2005, 18(12):1440-1463. 10.1016/j.echo.2005.10.005, 16376782.
16. Whalley GA, Gamble GD, Doughty RN, MacMahon S, Sharpe N. Selection bias in clinical research when subjects are excluded because of failure to estimate left ventricular mass by echocardiography. J Am Soc Echocardiogr 1998, 11:1050-1055. 10.1016/S0894-7317(98)70156-7, 9812098.
17. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. American Heart Journal 1949, 37(2):161-186. 10.1016/0002-8703(49)90562-1, 18107386.
18. Casale PN, Devereux RB, Kligfield P, Eisenberg RR, Miller DH, Chaudhary BS, Phillips MC. Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. Journal of the American College of Cardiology 1985, 6(3):572-580. 10.1016/S0735-1097(85)80115-7, 3161926.
19. Bruno G, Giunti S, Bargero G, Ferrero S, Pagano G, Perin PC. Sex-differences in prevalence of electrocardiographic left ventricular hypertrophy in Type 2 diabetes: The Casale Monferrato Study. Diabetic Medicine 2004, 21(8):823-828. 10.1111/j.1464-5491.2004.01246.x, 15270784.
20. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) 2007 Guidelines for the management of arterial hypertension. Eur Heart J 2007, 28(12):1462-1536. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
21. Srivastava PM, Calafiore P, Macisaac RJ, Patel SK, Thomas MC, Jerums G, Burrell LM. Prevalence and predictors of cardiac hypertrophy and dysfunction in patients with Type 2 diabetes. Clinical Science 2008, 114(4):313-320. 10.1042/CS20070261, 17916064.
22. Dawson A, Morris AD, Struthers AD. The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus. Diabetologia 2005, 48(10):1971-1979. 10.1007/s00125-005-1896-y, 16094529.
23. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, et al. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. N Engl J Med 2001, 345(12):861-869. 10.1056/NEJMoa011161, 11565518.
24. Havranek EP, Esler A, Estacio RO, Mehler PS, Schrier RW. Differential effects of antihypertensive agents on electrocardiographic voltage: results from the Appropriate Blood Pressure Control in Diabetes (ABCD) trial. American Heart Journal 2003, 145(6):993-998. 10.1016/S0002-8703(02)94780-0, 12796754.
25. Okin PM, Devereux RB, Gerdts E, Snapinn SM, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Lindholm LH, et al. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. Circulation 2006, 113(12):1588-1596. 10.1161/CIRCULATIONAHA.105.574822, 16534012.
26. Liu J, Masurekar MR, Vatner DE, Jyothirmayi GN, Regan TJ, Vatner SF, Meggs LG, Malhotra A. Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. American Journal of Physiology - Heart & Circulatory Physiology 2003, 285(6):H2587-2591.
27. Levy D, Labib SB, Anderson KM, Christiansen JC, Kannel WB, Castelli WP. Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation 1990, 81(3):815-820.
28. Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EJ, Vasan RS. Association of Plasma Natriuretic Peptide Levels With Metabolic Risk Factors in Ambulatory Individuals. Circulation 2007, 115(11):1345-1353. 10.1161/CIRCULATIONAHA.106.655142, 17339551.
29. Norman JE, Levy D, Campbell G, Bailey JJ. Improved detection of echocardiographic left ventricular hypertrophy using a new electrocardiographic algorithm. Journal of the American College of Cardiology 1993, 21(7):1680-1686. 10.1016/0735-1097(93)90387-G, 8496537.
30. Weber M, Dill T, Arnold R, Rau M, Ekinci O, M ̧ller KD, Berkovitsch A, Mitrovic V, Hamm C. N-terminal B-type natriuretic peptide predicts extent of coronary artery disease and ischemia in patients with stable angina pectoris. American Heart Journal 2004, 148(4):612-620. 10.1016/j.ahj.2004.04.021, 15459591.